Quality of lipid‐lowering therapy in patients with ischaemic heart disease: a register‐based study in 3477 patients

• Published in: Journal of internal medicine Vol. 255; no. 3; pp. 367 - 372
• Main Authors: Kanstrup, H., Lassen, J. F., Heickendorff, L., Lauritzen, T., Larsen, M. L.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01-03-2004; Blackwell Science; Blackwell Publishing Ltd
• Subjects: Aged; Biological and medical sciences; cholesterol; Cholesterol - blood; Denmark; Female; General aspects; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypolipidemic Agents - therapeutic use; ischaemic heart disease; lipid‐lowering therapy; Male; Medical sciences; Myocardial Ischemia - blood; Myocardial Ischemia - drug therapy; registers; Registries; statins; Denmark; Human; Cardiovascular disease; Lipids; Statin derivative; ischaemic heart disease; Cholesterol; Medicine; lipid-lowering therapy; Treatment; Ischemia; Register; Heart disease; Quality; statins; registers
• ISSN: 0954-6820; 1365-2796
• DOI: 10.1111/j.1365-2796.2003.01299.x

.
Objective.  To develop a method to evaluate routine management practices concerning lipid‐lowering treatment in patients with ischaemic heart disease (IHD) in a large geographic area.
Design.  A register‐based study linking information on IHD with cholesterol levels and prescriptions on lipid‐lowering medications by personal registration number. Plasma cholesterol levels were collected from the electronic laboratory information system (LIS), and information on IHD from the Danish National Hospital Register (LPR). The extent of treatment was evaluated by information on prescriptions on lipid‐lowering medications from the Danish National Health Service.
Setting.  Evaluates treatment in both hospitals and primary care.
Subjects.  Patients with IHD.
Results.  In total 3477 patients <75 years were identified, and 43.7% had claimed prescriptions on lipid‐lowering medications (01.01.2000–31.07.2000). In the whole population, 42% reached the goal for total cholesterol lower than 5 mmol L−1 set by European guidelines. In the 1521 patients treated with lipid‐lowering medications 55% reached the goal.
Conclusion.  By use of registers it was possible to develop a method to evaluate and monitor current treatment practice for dyslipidaemia in a large geographic area. The method makes it possible to evaluate the impact of guidelines, changes in treatment procedures and to provide feedback to physicians. The study revealed that lipid‐lowering treatment is still not sufficiently implemented in clinical practice even in patients with known IHD, and the used doses of statins are lower than those used in randomized clinical trials.